SCHEMBL3134835

SCHEMBL3134835

CN(CC(=O)N1CCN(Cc2ccc3c(c2)OCO3)CC1)c1ccc(Oc2ccc(N)cc2)cc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 6/20 0.60
MEN1 O00255 5/20 0.60
MAPT P10636 3/20 0.58
POLB P06746 1/20 0.58
LMNA P02545 4/20 0.56
SMN1; SMN2 Q16637 5/20 0.56
CYP3A4 P08684 2/20 0.55
ABCB11 O95342 1/20 0.55
CYP1A2 P05177 1/20 0.55
ADRA2A P08913 1/20 0.55
CYP2D6 P10635 1/20 0.55
CHRM1 P11229 1/20 0.55
TBXA2R P21731 1/20 0.55
SLC6A2 P23975 1/20 0.55
SLC6A4 P31645 1/20 0.55
CYP2C19 P33261 1/20 0.55
ADRA1A P35348 1/20 0.55
OPRM1 P35372 1/20 0.55
DRD3 P35462 1/20 0.55
SLC6A3 Q01959 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12315672 0.89 SMN1; SMN2 (0.66) KMT2AMEN1MAPTPOLBLMNA
SCHEMBL3138333 0.84 MEN1 (0.56) KMT2AMEN1MAPTPOLBLMNA
SCHEMBL11896885 0.82 LMNA (0.51) KMT2AMEN1MAPTPOLBLMNA
SCHEMBL3134828 0.81 KMT2A (0.57) KMT2AMEN1MAPTPOLBLMNA
SCHEMBL3139370 0.81 KDM4E (0.51) KMT2AMEN1MAPTPOLBLMNA
SCHEMBL3142788 0.81 SMN1; SMN2 (0.51) KMT2AMEN1MAPTPOLBLMNA
SCHEMBL8913178 0.80 ALDH1A1 (0.71) KMT2AMEN1MAPTPOLBLMNA
SCHEMBL12315670 0.80 SMN1; SMN2 (0.67) KMT2AMEN1MAPTPOLBLMNA
SCHEMBL3143560 0.78 SMN1; SMN2 (0.48) KMT2AMEN1MAPTPOLBLMNA
SCHEMBL3142939 0.77 LMNA (0.48) KMT2AMEN1MAPTPOLBLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8236826-B2 Diarylether derivatives as antitumor agents OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2012-08-07 US disclosed
US-8188277-B2 Aromatic compounds for suppressing the generation of collagen OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2012-05-29 US disclosed
US-20100004438-A1 DIARYLETHER DERIVATIVES AS ANTITUMOR AGENTS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2010-01-07 US disclosed
US-20070270422-A1 Aromatic Compounds OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-11-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100004438-A1 DIARYLETHER DERIVATIVES AS ANTITUMOR AGENTS ROS1, CBR1, CBR3 KMT2A 1623/4885MEN1 1851/4885MAPT 4866/4885
US-20070270422-A1 Aromatic Compounds COL1A1, COL2A1, COL14A1 KMT2A 2349/4885MEN1 3512/4885MAPT 4163/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.